

ersonal use only



Phase II - USAISR Platelet Results

22 May 2026

Vitrafy Life Sciences Limited (ASX: VFY)
ACN 622 720 254

vitrafy.com
Strictly Private & Confidential



Important Notice and Disclaimer

This presentation is provided by Vitrafy Life Sciences Limited (ACN 622 720 254) (the Company). Statements in this presentation are made only as at the date of this presentation and the information in this presentation remains subject to change without notice. The information in this presentation is of a general nature and does not purport to be complete, is provided solely for information purposes of giving you summary information and background about the Company and its activities, current as at 20 May 2026, and should not be relied upon by the recipient.

This presentation is not, and does not constitute, or form any part of, an offer to sell or issue, or the solicitation, invitation or recommendation to purchase any securities.

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation.

This presentation does not purport to summarise all information that a recipient should consider when making an investment decision, and should not form the basis of any decision by a recipient.

Recipients should carry out their own investigations and analysis of the Company and verify the accuracy, reliability and completeness of the information contained in this presentation or any other form of communication to which the recipient is permitted access in the course of evaluating an investment in the Company.

No liability

To the maximum extent permitted by law, the Company, or their respective affiliates or related bodies corporate or any of their respective officers, directors, employees, agents and advisers (Related Parties), nor any other person, accepts any responsibility or liability for, and makes no recommendation, representation or warranty concerning, the content of this presentation, the Company, or the Company's securities including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it.

Eligible recipients

This presentation is provided to you as an investor to whom an offer document is not required to be given, and no registration, lodgement or other formality is required, in connection with an offer of securities. In accepting this presentation you warrant that you are an investor within the scope of this paragraph and that you accept this presentation on the basis set out in this notice.

This presentation is not, and does not constitute, or form any part of, an offer to sell or the solicitation, invitation or recommendation to purchase any securities in the United States and neither this presentation nor anything contained herein shall form the basis of any contract or commitment. This presentation may not be distributed or released in the United States. Securities may not be offered or sold in the United States unless such securities are registered under the U.S. Securities Act of 1933, as amended (U.S. Securities Act) or in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and any other applicable securities laws. Each institution or person that reviews this presentation will be deemed to represent that each such institution or person is not in the United States.

The distribution of this presentation may be restricted by law. Persons who come into possession of this presentation should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws.

Confidentiality

This presentation is confidential and not for further distribution. It is provided by the Company on the basis that, by accepting this presentation, persons to whom this presentation is given agree to keep the information confidential, not copy the presentation and not to disclose it, in whole or in part, to anyone within their organisation except on a need-to-know basis and subject to these restrictions, or to anyone outside their organisation.

Key Highlights

USAISR results confirm Vitrafy cryopreservation ecosystem outperforms regulatory and quality standards across all platelet protocols tested.

94%

Post thaw recovery - no-wash protocol, with high functionality across all quality measures

Independent
US Army
Validation

Largest blood platelet testing program in commercial volumes, using the Vitrafy cryopreservation ecosystem

Category First
Opportunity

Position the Company to address this critical market gap

Phase II In-Vitro Study Background & Aims



Study Aim

Assess and determine Vitrafy's cryopreservation ecosystem **capability** to successfully cryopreserve critical response **blood platelets**.



CRADA Framework

Conducted under the Cooperative Research and Development Agreement (**CRADA**) between Vitrafy and the U.S. Army.



Independent Validation

Conduct independent, **U.S. Army-authored validation** by the U.S. Army Institute of Surgical Research ahead of FDA Medical Device registration.



Rapid Deployment Capability

Establish a practical operational solution for a rapidly deployable cryopreserved platelet product (**decentralised no wash** protocol).



Largest Testing Program to Date

Apheresis platelets from **20 donors / 60+ samples** tested via the Vitrafy ecosystem using 3 protocols.




IPO Commitment Delivered

USAISR Phase II validation was a **core deliverable** identified at Vitrafy's November 2024 IPO — **now completed**.

Results - Platelet Recovery vs Fresh

All protocols tested using Vitrafy's cryopreservation ecosystem exceeded the regulatory standard and quality guidelines. 3% DMSO no-wash protocol delivered the highest performance with a 94% post-thaw recovery


Phase II Post-Thaw Platelet Recovery - % of Pre-Freeze (Fresh) Baseline



Results - Platelet Functionality vs Fresh

Key platelet functionality metrics were measured post thaw – including clot strength and the retention of key surface receptors.

Functionality Markers — % of Pre-Freeze (Fresh) Baseline



Outlook

In Vitro validation milestone complete— multiple pathways now activated.

FDA medical device registration (GUARDION) – H1 FY27

Phase II Results Publication (military & civilian) – H1 FY27

FDA, Military & Civilian blood network engagement